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Background. Norovirus infection is the most common cause of acute self-limiting gastroenteritis. Only 3 cases
of chronic norovirus infection in adult solid organ transplant recipients have been reported thus far.
Methods. This case series describes 9 consecutive kidney allograft recipients with chronic norovirus infection
with persistent virus shedding and intermittent diarrhea for a duration of 97–898 days. The follow-up includes
clinical course, type of immunosuppression, and polymerase chain reaction for norovirus. Detailed molecular
analyses of virus isolates from stool specimens over time were performed.
Results. The intensity of immunosuppression correlated with the diarrheal symptoms but not with viral
shedding. Molecular analysis of virus strains from each patient revealed infection with different variants of GII.4
strains in 7 of 9 patients. Another 2 patients were infected with either the GII.7 or GII.17 strain. No molecular
evidence for nosocomial transmission in our outpatient clinic was found. Capsid sequence alignments from follow-
up specimens of 4 patients showed accumulation of mutations over time, resulting in amino acid changes pre-
dominantly in the P2 and P1–2 region. Up to 25 amino acids mutations were accumulated over a 683-day period
in the patient with an 898-day shedding history.
Conclusion. Norovirus infection may persist in adult renal allograft recipients with or without clinical symp-
toms. No evidence for nosocomial transmission in adult renal allograft recipients was found in our study. Molecular
analysis suggests continuous viral evolution in immunocompromised patients who are unable to clear this infection.
Noroviruses represent the most common cause of acute
gastroenteritis in adults and older children worldwide.
They belong to the family of the Caliciviridae, genus
Norovirus. The first description was an outbreak in Nor-
walk reported in 1968, and the virus was named Nor-
walk virus thereafter. A wide range of genetically distant
norovirus strains are organized into 5 genogroups and
further classified into at least 27 genetic clusters or
genotypes [1]. They are small (30 nm), single-stranded
RNA viruses with a simple structure containing 1 major
(VP1, capsid) and 1 minor (VP2) protein and no en-
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velope. The genogroups GI, GII, and GIV include hu-
man pathogens, and the genotype II.4 has predomi-
nated in outbreaks, which were associated with epochal
emergence of GII.4 variants [2–4].
The major route of transmission is fecal-oral when
the patient is most symptomatic, but there is evidence
of pre- and postsymptomatic transmission as well as
occasional airborne transmission due to aerosolized vi-
ruses during vigorous emesis [5]. Noroviruses are ex-
tremely contagious and highly resistant to inactiva-
tion by freezing, heating, and exposure to detergent-
based cleaners. The incubation period is short (24–48
h). The typical clinical presentation is an abrupt ill-
ness with vomiting and diarrhea, headache, or consti-
tutional symptoms. Fever is present in one-half of
patients. Symptoms generally last 24–60 h and are self-
limited, but severe disease has been reported in elder-
ly and immunocompromised patients.
Norovirus shedding in stool assessed by immune
electron microscopy or antigen-capture enzyme-linked
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Figure 1. Correlation of immunosuppressive treatment with clinical symptoms and viral shedding. All patients received calcineurin inhibitor–based
immunosuppression. Chronic norovirus shedding was observed over 97–898 days. The occurrence of clinical symptoms but not C-reactive protein levels
and viral shedding correlated with the intensity of immunosuppression. F, female; M, male; P1–P9, patients 1–9. The number after sex indicates the
patient’s age.
immunosorbent assay is rarely detected beyond 72 h after the
onset of illness, but a prolonged shedding may be detected by
using polymerase chain reaction (PCR) [6, 7]. It has been re-
ported that levels of viral load in genogroup II infections is
higher than in genogroup I [8]. In immunocompetent patients
after experimental human infection virus, shedding up to 56
days has been described [9]. Siebenga et al [10] reported pro-
longed illness and viral shedding (21–182 days) in hospitalized
patients. Chronic norovirus infection has been reported in pe-
diatric intestinal transplant recipients and in a child with car-
tilage hair hypoplasia after bone marrow transplantation [11–
13]. Ludwig et al [14] found a prolonged shedding over a
maximum of 433 days in pediatric patients with cancer. Among
adult solid organ transplant recipients, chronic excretion has
only been reported in 1 patient undergoing heart transplant
[15] and very recently in 2 renal transplant recipients [16].
Here, we describe a series of 9 consecutive cases of chronic
norovirus infection in renal allograft recipients. To assess a
potential nosocomial transmission and viral evolution over
time, we performed a detailed molecular analysis, which ex-
cluded transmission in the outpatient clinic but revealed in-
creasing accumulation of mutations in the capsid gene over
time.
PATIENTS AND METHODS
Patient screening and assessment. Renal transplant recipients
presenting with prolonged or severe diarrhea were evaluated
for infectious and noninfectious causes. In addition to routine
assessment for bacterial or viral infection with stool cultures
(for detection of Campylobacter, Salmonella, Shigella, and for
patients with severe symptoms, protozoae), specific testing for
Clostridium difficile toxin, and plasma PCR for cytomegalovirus,
we performed PCR for norovirus from stool specimens. From
November 2006 through November 2008, 78 patients were
screened, and 13 (16.7%) were found to have positive PCR
results for norovirus. If norovirus was detected, 2 additional
PCR examinations were performed in the following 3 months,
even if the patient had resolved all symptoms. Chronic noro-
virus infection was defined as 3 positive stool specimens during
a follow-up of at least 3 months. Nine patients with viral shed-
ding 13 months were found. In our 9 patients, over all 60
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Table 1. Patient Characteristics
Characteristic
All patients
(n p 9)
Sex
Female 2 (22)
Male 7 (78)
Age, median years (range) 46 (23–59)
Renal disease
Glomerulonephritis 3 (33)
Hypoplasia/ Aplasia 3 (33)
Others 3 (33)
Duration of dialysis, median months (range) 29 (3–136)
Hemodialysis 5 (56)
Peritoneal dialysis 4 (44)
Transplantation
Prior transplantations, median no (range) 1 (1–2)
Living donor kidney 3 (33)
Deceased donor kidney 6 (67)
Induction therapy 2 (22)
Rejections, median no (range) 1 (1–2)
Rejection treatment
Prednisone 6 (67)
ATG/OKT3 2 (22)
Immunoadsorption 1 (11)
Initial immunosuppression
Dual immunosuppression
With CyA 0 (0)
With tacrolimus 2 (22)
Triple immunosuppression
With CyA 2 (22)
With tacrolimus 5 (56)
Antimetabolite
Mycophenolate mofetil 6 (67)
Mycophenolic acid 2 (22)
Azathioprine 1 (11)
Prednisone 7 (78)
Norovirus infection
Start after last transplantation,
median months (range) 42 (1.3–136)
CRP level at initial presentation,
median mg/L (range) 1 (1–38)
Need for patient hospitalization 5 (56)
Duration of symptoms, median days (range) 150 (24–898)
Intermittent symptoms 5 (56)
Duration of shedding, median days (range) 230 (97–898)
Viral clearance 3 (33)
NOTE. Data are no (%) of patients, unless otherwise indicated. CRP, C-
reactive protein; CyA, cyclosporin A.
samples were analyzed (mean, 6.67 samples tested per patient).
Figure 1 shows sample numbers in chronological sequence for
each patient. Clinical symptoms, immunosuppression dose, and
C-reactive protein levels were recorded at every visit. Further-
more, 7 of our 9 patients underwent colonoscopy and gas-
troscopy. In case of persistent norovirus infection during the
first 3 months after initial diagnosis, PCR for norovirus was
regularly performed every 3 months thereafter and was only
stopped after 2 consecutive negative results. Duration of shed-
ding was defined by the dates of first positive and first negative
PCR results. Family members were not tested.
PCR and molecular analysis. Analysis of stool specimens
for the presence of norovirus was performed at the Institute
of Medical Virology, University of Zu¨rich, Switzerland. Stool
specimens were diluted 10-fold with phosphate-buffered saline,
were frozen over night at 20C, and after thawing, were cen-
trifuged in a table top centrifuge at 1000 g for 15 min. On the
basis of threshold cycle values of the real time PCR, we divided
positive specimens into groups with very high, high, and av-
erage/low virus concentration. Diagnostic PCR for norovirus
genogroup I and II were performed as described by Ho¨hne and
Schreier [17].
To analyze the polymerase genotype, a 297-basepair fragment
of region A [18] was amplified from the first available stool
sample of all 9 patients and sequenced directly as described
elsewhere [19]. The accumulation of mutations in the capsid
gene was analyzed in follow-up samples obtained from 4 pa-
tients (patients 3, 4, 5, and 7). Therefore, the entire ORF2 gene
region was reverse transcribed and amplified in the first round
reverse transcription PCR using SuperScript III One-Step RT-
PCR System with Platinum Taq High Fidelity, according to the
manufacturer’s instructions (Invitrogen), with primers NV107a
(sense, 5′-AGCCAATGTTCAGATGGATG-3′) and NV100 (an-
tisense, 5′-GCAAAGAAAGCCTCCAGCCAT-3′). The 1-step re-
verse transcription PCR was performed at 55C for 5 min, 45C
for 55 min, and 94C for 2 min, followed by 40 cycles at 94C
for 15 s, 45C for 30 s, and 68C for 2 min, and finally, a 5
min elongation at 68C. For the nested PCR, primers NV271
(sense, 5′-ATGAAGATGGCGTCGAATGA-3′) and NV288 (an-
tisense, 5′-TAAAGCACGCCTGCGCCCCG-3′) and Platinum
Pfx DNA polymerase (Invitrogen) were used. Amplicons were
purified from agarose gels with use of the MinElute Gel Ex-
traction Kit (Qiagen), or from solution with use of ExoSap-It
(GE Healthcare). Purified amplicons were sequenced directly
using the BigDye terminator cycle sequencing kit and an ABI
3130xI Genetic Analyzer (Applied Biosystems). Sequences were
aligned to prototype sequences drawn from GenBank with use
of CLUSTAL W, version 1.6, and phylogenetic trees were pro-
duced using the neighbor joining and DNADIST program of
the Phylogeny Interference Package (PHYLIP), version 3.57c.
Nucleotide sequences of the capsid gene from the first and the
last specimen amplified were submitted to GenBank (accession
numbers, GQ266690–GQ266697).
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Figure 2. Sequence analysis of a polymerase gene fragment from all 9 patients. Neighbor-joining tree of a 297 nucleotide– long fragment of the
polymerase gene (region A). Sequences were obtained from the first stool specimens available for all 9 patients (P1–P9). Prototype sequences (bold, italics)
from GenBank are II.1 Hawaii (U07611), II.3 Toronto (U02030), II.4 2006A Terneuzen70 (EF126964), II.4 2006B Nijmegen115 (EF126966), II.7 Leeds (AJ277608),
and II.17 Sommieres1203/2006 (EF529742). Bootstrap values 170% are indicated. The scale represents nucleotide substitutions per site.
RESULTS
Patient characteristics. Nine consecutive patients (7 men and
2 women) with a renal allograft and gastroenteritis due to
chronic norovirus infection were identified from November
2006 through November 2008 and were followed up until April
2009. The age of the patients at onset was 23–59 years. No-
rovirus infection started between 1.3–125 months after trans-
plantation (median, 42 months). At the onset of norovirus
infection, 7 patients were receiving standard triple immuno-
suppression with a calcineurin inhibitor, mycophenolate mo-
fetil, and prednisone; 2 patients were receiving dual immu-
nosuppression with a calcineurin inhibitor and mycophenolate
mofetil; 7 patients were receiving tacrolimus; and 2 patients
were receiving cyclosporine A (Table 1).
Clinical course of norovirus infection. Duration of chronic
virus shedding ranged from 97 to 898 days (Figure 1). A very
high virus concentration (threshold cycle value, 15–20; mean,
17.29) was found in 18.4%, and a high concentration (threshold
cycle value, 120–30; mean, 24.22) was in 71.4% of all positive
specimens. In 10.2% of samples with positive PCR results for
norovirus, the concentration was low to average (threshold
cycle value, 130–38; mean, 34.45); in most of these, the fol-
lowing PCR for norovirus had a negative result. In all cases,
diarrhea led to a reversible prerenal decrease of renal function.
Five patients were hospitalized because of severe dehydration
and allograft dysfunction. Symptoms of overt diarrhea, irreg-
ularly formed stools, and/or abdominal bloating and pain in
repeated consultations lasted 24–898 days. Patient 3 had the
longest follow-up, with chronic viral shedding over 898 days,
and intermittent clinical symptoms were documented over the
whole study period after detection of the first positive stool.
At initial presentation, C-reactive protein was mildly elevated
(median, 1 mg/L; range, 1–38 mg/L), whereas in the asymp-
tomatic shedding phase, the C-reactive protein level remained
normal except for episodes associated with other infections.
Three of the 9 patients cleared the virus during the observation
period after 104–379 days. Because of the lack of a specific
therapy, a cautious decrease of immunosuppression was initi-
ated if possible, mainly by reduction or withdrawal of pred-
nisone or mycophenolate mofetil. Two patients were switched
from mycophenolate mofetil to azathioprine because it is as-
sociated with fewer gastrointestinal adverse effects. Reduction
of immunosuppression led to clinical amelioration or full re-
covery in all patients, but norovirus shedding only stopped in
3 patients.
Results of sequence analysis I: no evidence for nosocomial
transmission. Sequence analysis of region A in the polymerase
gene (Figure 2) and region C (5′ end of the capsid gene; data
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Figure 3. Sequence analysis of the capsid gene in follow-up samples from 4 patients. Neighbor-joining tree based on alignments of 1596 nucleotide–
long fragments of capsid gene sequences from patients 3, 4, 5, and 7. Prototype sequences (bold, italics) from GenBank are II.1 Hawaii (U07611), II.3
Toronto (U02030), II.4 2006A Terneuzen70 (EF126964), II.4 2006B Nijmegen115 (EF126966), II.17 CS-E1/2002 (AY502009), and II.17 Katrina-17/2005
(DQ438972). Bootstrap values 170% are indicated. The scale represents nucleotide substitutions per site.
Figure 4. Rate of amino acid change fixation of norovirus recovered
from patient 3. During the first 262 days of chronic norovirus infection,
an accumulation of 0.049 amino acid changes/day occurred, compared
with 0.028 amino acid changes/day during days 262–683.
not shown) revealed that patients 2, 3, 4, and 8 were infect-
ed by GII.4 variant 2006A (prototype sequence Terneuzen/
70/2006; GenBank accession number EF126964), and patients
1, 5, and 9 were infected by GII.4 variant 2006B (prototype
sequence Nijmengen115/2006; GenBank accession number
EF126966), with DNA distances of 0.0102–0.0345 among each
other. Furthermore, comparison of nearly full-length capsid
sequences of the earliest samples available from patients 2, 3,
and 4 (all infected with GII.4 2006A) demonstrated 1.7%–2.4%
differences in nucleic acid and 1%–1.5% differences in amino
acid sequences. In patients 6 and 7, the non-GII.4 genotypes
GII.7 and GII.17 were detected, respectively. All patients re-
mained infected by the initially detected strain throughout the
period of the study. Because of the finding of 3 different ge-
notypes and 2 variants of GII.4, no evidence for nosocomial
transmission in the outpatient clinic was found for the 9 pa-
tients analyzed.
Results of sequence analysis II: evidence for viral evolution.
To study viral evolution, nearly full-length sequences of the
capsid gene (1596 nucleotides long) in follow-up samples from
4 patients (patients 3, 4, 5, and 7) were analyzed, and the
neighbor-joining tree is shown in Figure 3. In 5 serial stool
specimens from patient 3 (infected by GII.4 2006A; shedding
over 898 days) obtained over a period of 683 days, 46 nucleotide
changes occurred, resulting in 25 amino acid changes. The
accumulation and fixation of amino acid changes resulted in
an overall fixation rate of 0.037 amino acids/day. Interestingly,
a biphasic pattern with a decreased fixation rate after day 262
was observed (0.049 before day 262 and 0.027 after day 262),
which may be related to a reduction of immunosuppressive
therapy (ie, stop of prednisone; Figure 4). Twenty-one of 25
amino acid changes were accumulated in the P2 and P1–2
domain (amino acids 294–459), including amino acid substi-
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Figure 5. Amino acid substitutions in the capsid gene during long-term shedding from patients 3, 4, 5, and 7. Capsid domains are indicated in the
first bar. Changing amino acid positions are shown at the top of the 1-letter amino acid code. Gray boxes indicate informative sites according to
Siebenga et al [10], and asterisks indicate hot spots according to Allen et al [20]. Labeled bars indicate amino acid positions belonging to antigenic
sites A and B.
tutions at positions 296–298 and 393, which are considered to
be sites putatively associated with antigenic changes (site A,
amino acids 296–298; site B, amino acids 393–395) [20]. In
patient 4, who was also infected by GII.4 2006A, 22 nucleotide
changes resulting in 14 amino acid changes were found after
281 days (0.049 amino acid changes/day). Twelve amino acid
changes occurred in the P1 and P2 domain positions 256 and
450, and 1 each occurred in the extreme N- and C-termini of
the capsid protein (amino acid 6 and amino acid 521, respec-
tively). Also in this patient, amino acid substitutions occurred
in site A and B. The 2 other patients demonstrated more re-
duced fixation rates. Patient 5 (infected by GII.4 2006b) had a
fixation rate of 0.012 amino acid changes/day (2 amino acid
changes, 3 nucleotide changes) after 161 days of infection, and
in patient 7, (infected by GII.17) a fixation rate of 0.013 amino
acids/day was observed after 384 days of chronic infection (6
amino acid changes, 10 nucleotide changes). All amino acid
changes observed in the capsid gene of the 4 patients are rep-
resented in Figure 5.
DISCUSSION
This study presents a detailed clinical and molecular analysis
of a series of 9 adult renal allograft recipients with chronic
norovirus infection. This infection in immunocompetent pa-
tients is usually self-limiting and of short duration. Virus shed-
ding 13–56 days after inoculation has been described in ex-
perimentally infected volunteers [9]. Kirkwood [21] investi-
gated 8 children recovering from norovirus gastroenteritis and
demonstrated a shedding for at least 25 days in 3 children and
up to 100 days in 1 child. Prolonged asymptomatic shedding
has been reported in special groups of immunocompromised
patients, such as small children or geriatric hospitalized indi-
viduals [10, 22]. In adult solid organ transplant recipients,
chronic excretion has been reported in 1 heart transplant pa-
tient [15]. Westhoff et al [16] found virus shedding in 2 kidney
allograft recipients over a maximum of 7.5 months. In our
series, we found chronic virus shedding in 9 kidney allograft
recipients with a median shedding duration of 230 days and a
maximum of 898 days. Clinical symptoms lasted 24–898 days.
Initial clinical presentation was acute gastroenteritis, as ex-
pected, whereas further clinical follow-up was more hetero-
geneous. Although no specific therapy for this infection is avail-
able, intravenous fluid and electrolyte substitution and hos-
pitalization was required in severe cases. Reduction of im-
munosuppression may be indicated in situations with severe
symptoms and chronic shedding. Adjustment of immunosup-
pression needs to be performed with great care and must be
individualized for each patient. Blood levels of calcineurin in-
hibitors, in particular tacrolimus, tend to increase during symp-
tomatic episodes and should be adjusted [23, 24]. Intensity and
duration of symptoms as well as virus shedding were influenced
by dosage reductions of steroids or mycophenolate mofetil or
by a switch from mycophenolate mofetil to azathioprine. Be-
cause we did not alter tacrolimus or cyclosporine treatment,
no conclusions can be made with regard to the role of calci-
neurin inhibitors. Interestingly, after reduction of immuno-
suppression most recipients were able to recover completely
despite chronic virus shedding after a phase of stool irregular-
ities (loose stool without diarrhea or meteorism). Thus, in renal
allograft recipients presenting with diarrhea, norovirus should
be included in the differential diagnosis. PCR for norovirus in
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stool samples is routinely available and should be included in
the work-up of these patients.
Molecular analysis of norovirus isolates, including follow-up
specimens, was performed with the following 2 aims: (1) ad-
dressing a potential nosocomial transmission and (2) evaluating
virus evolution over time under a reduced immune pressure
due to maintenance immunosuppressive treatment. Contami-
nation of environmental surfaces, such as sanitary equipment,
scales, or objects in the examination room, is known to play
a role in norovirus transmission [25, 26]. Therefore, hospital-
ized symptomatic patients with proven norovirus infection are
usually isolated. However, in the outpatient setting with chron-
ically infected patients the situation is less clear. Recently, Xerry
et al [27] demonstrated that a point source outbreak is char-
acterized by 100% nucleotide similarity in the capsid P2 domain
among strains from different patients. In contrast, in our 9
patients 3 different norovirus genotypes were detected. Fur-
thermore, among the 7 patients infected with genotype II.4, 2
variants (2006A and 2006B) differing 1%–6% in the nucleotide
sequences of the capsid region were identified. Thus, although
in our outpatient clinic all renal transplant recipients share a
common waiting area and use the same toilets, the molecular
analysis of virus strains showed no evidence of nosocomial
transmission. This surprising observation may be explained by
a lower amount of virus shedding and/or a lower infectiousness
of mutated viruses in chronically infected patients, compared
with acute norovirus infection. However, this has not yet been
proven, and therefore, the exact role of contact isolation in
asymptomatic and symptomatic solid organ recipients in the
outpatient clinic setting still needs to be defined.
The second goal of molecular analysis was to assess viral
evolution in chronically infected patients shedding norovirus
over several months. By comparison of subsequent epidemic
variants of GII.4 strains, the existence of several hotspots of
amino acid variation across the P domain has been demon-
strated [2, 3, 28]. Analysis of mutations at these hotspots and
their mapping onto the 3D crystal structure revealed 2 surface-
exposed sites in the P2 domain (site A and site B, both 3 amino
acid residues in length) which were strongly associated with
the emergence of epidemiologically distinct virus strains [20].
Binding studies using monoclonal antibodies confirmed that
site A and B form a conformational, variant-specific epitope
which is involved in antibody binding, possibly leading to es-
cape mutants [29]. In all 3 GII.4-infected patients in this study,
most of amino acid changes occurred within the hotspots de-
scribed for the emergence of new variants. In patient 3, with
an 898-day shedding history, 14 of 17 amino acid substitutions
occurred among amino acid residues 294 and 425, including
amino acid changes at all 3 positions of site A (amino acid
residues 296-298) and 1 amino acid substitution at site B (amino
acid 393). In contrast, all 6 amino acid mutations found in patient
7, who was infected with GII.17, occurred outside the hotspots
described for GII.4 strains. On the basis of crystal structure anal-
ysis of a Lordsdal-like GII.4 P protein (VA387 strain), Cao et al
[28] located the receptor binding pocket responsible for binding
to a-fucose of the histoblood group antigens at the outermost
end of the P domain (amino acid residues Ser-343, Thr-344, Arg-
345, Asp-374, Cys-441, Ser-442, and Gly-443). In all of our 4
patients analyzed, no amino acid substitutions at these sites were
observed, but in all 3 GII.4-infected patients, the amino acid at
position 340 was changed, which is close to the receptor binding
site (amino acids 343–345). Donaldson et al [30] suggested that
just a few amino acid changes within the P2/P1 domain can
influence the antigenicity and the receptor usage, leading to an
increasing ability of the virus to persist. The relatively low amino
acid accumulation rates of our patients, which seem to be at-
tributable to their impaired immunity, confirm the data reported
by Siebenga et al [10], who studied patients of different levels
of immunodeficiency. Patients with highly or mildly impaired
immune response demonstrated a fixation rate of 0.03 and 0.07
amino acid changes per day, respectively, whereas 0.13 amino
acid changes per day were found in an otherwise healthy patient.
Thus, amino acid changes within the P2 surface also detected in
solid organ allograft recipients receiving maintenance immu-
nosuppression showed that even a weak immune pressure causes
modification of the capsid protein to evade immune recognition,
which may be part of the persistence strategy of norovirus.
Taken together, to our knowledge, this study for the first
time presents a series of renal allograft recipients with chronic
norovirus infection, including a molecular analysis of norovirus
isolates. Norovirus infection in immunosuppressed patients can
occur for up to 898 days with or without clinical symptoms.
The implications for hospital hygiene procedures in inpatients
and outpatients have to be defined. Molecular analysis dem-
onstrated no evidence of nosocomial transmission in our out-
patient clinic but suggested immunity-driven virus evolution.
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